bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

by Maria Zannes | Apr 24, 2024 | Press Releases

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth Collaboration with the US Department of Defense’s largest military health organization underway SAN ANTONIO, Texas (April 24, 2024) – bioAffinity Technologies,...

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

by Maria Zannes | Apr 9, 2024 | Press Releases

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening SAN ANTONIO, Texas (April 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) , a biotechnology company focused on the need for...

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

by Maria Zannes | Apr 1, 2024 | Press Releases

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results SAN ANTONIO, Texas (April 1, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) , a biotechnology company focused on commercializing noninvasive tests for the detection...

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

by Maria Zannes | Mar 8, 2024 | Press Releases

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO, Texas (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) today announced it has closed a securities purchase...

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

by Maria Zannes | Mar 6, 2024 | Press Releases

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO, Texas (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) today announced it has entered into a securities...

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

by Maria Zannes | Mar 5, 2024 | Press Releases

Increasing physician interest, newly approved reimbursement code driving growth SAN ANTONIO, Texas (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...
« Older Entries
Next Entries »

Categories

  • Articles (28)
  • Events (38)
  • News (53)
  • Press Releases (142)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 October 7, 2025
  • bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering September 29, 2025
  • bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung September 26, 2025
  • bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 September 17, 2025
  • Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules September 9, 2025
CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.